Arthritis News and Research

Latest Arthritis News and Research

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Patients with severe rheumatoid arthritis more likely to have heart problems

Patients with severe rheumatoid arthritis more likely to have heart problems

Lupus disparities: Young, black women have highest rate of developing lupus

Lupus disparities: Young, black women have highest rate of developing lupus

Autoimmune link to schizophrenia

Autoimmune link to schizophrenia

Researchers explore the origin of sweat gland stem cells

Researchers explore the origin of sweat gland stem cells

Inflammation causally linked to functional decline in aging

Inflammation causally linked to functional decline in aging

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma partners with Almac to provide combined service for drug development

Clinical trials will help to develop treatment and follow-up of COPD patients

Clinical trials will help to develop treatment and follow-up of COPD patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Arthritis Society launches campaign to urge Canadians to speak up, "Share The Pain"

Arthritis Society launches campaign to urge Canadians to speak up, "Share The Pain"

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Psychotic symptoms alone denote medical health risk

Psychotic symptoms alone denote medical health risk

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.